Locus Biosciences
Raleigh, US · Founded 2015 · Delaware corporation · 57 employees on LinkedIn · 8 known investors
Locus Biosciences develops engineered bacteriophage therapies for treating bacterial infections and conditions in immunology, oncology, and CNS disorders. It uses a technology platform combining robotics, automated biobanking, AI-driven cocktail prediction, and synthetic biology, and operates a cGMP viral vector manufacturing facility for clinical trial material.
Founders & leadership
Locus Biosciences was founded in 2015 by Paul Garofolo.
PG
Paul GarofoloCEO & Co-founder
NT
NICK TAYLORExecutive
PG
PAUL GAROFOLOExecutive
NC
Nick ConleyVice President of Technology (Co-founder of EpiBiome, acquired by Locus)
Board
GG
GEOFFREY GLASSBoard director
DJ
DAVID JOHNSTONBoard director
BB
BARY BAILEYBoard director
CB
CHUCK BRAMLAGEBoard director
Investors · 8
Artis Ventures✓ verifiedSan Francisco · $50K – $25M
Abstract VenturesSan Francisco · $250K – $750K
Hemisphere Ventures LLCMckinney
Domain AssociatesreportedPrinceton · $200K – $15M
Longitude CapitalreportedMenlo Park · $10M – $30M
Starlight VenturesreportedMiami · $100K – $3M
Also in the syndicate · 2
Braeburn CapitalJohnson & Johnsonlead
Funding
SEC filings, press & company announcements$46.3M disclosed across 6 of 7 rounds · 2016–2024
- Undisclosed amountSeries CFeb 2024
Johnson & Johnson (lead), Braeburn Capital, Domain Associates, Longitude Capital
Source ↗
▶$10.6MraisedFeb 2022 · 3 investors · BiotechnologyRule 506(b)
▶$10.6MraisedFeb 2022 · 3 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Bary BaileyDirector
- David OusteroutExecutive Officer
- Joseph NixonExecutive Officer
- Stuart PetersonDirector
- Paul GarofoloExecutive Officer, Director
- Offering amount
- $20M
- Amount sold
- $10.6M
- First sale
- Jan 2022
- Incorporated
- Corporation, Delaware, 2017
- Federal exemptions
- 06b
▶$20MraisedNov 2020 · 34 investors · BiotechnologyRule 506(b)
▶$20MraisedNov 2020 · 34 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- STUART PETERSONDirector
- BARY BAILEYDirector
- PAUL GAROFOLOExecutive Officer, Director
- Offering amount
- $20M
- Amount sold
- $20M
- First sale
- Apr 2020
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$7MraisedJul 2018 · 24 investors · BiotechnologyRule 506(b)
▶$7MraisedJul 2018 · 24 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- STUART PETERSONDirector
- BARY BAILEYDirector
- PAUL GAROFOLOExecutive Officer, Director
- Offering amount
- $7M
- Amount sold
- $7M
- First sale
- Jul 2018
- Incorporated
- Corporation, Delaware, 2015
- Federal exemptions
- 06b
▶$7MraisedOct 2017 · 2 investors · BiotechnologyRule 506(b)
▶$7MraisedOct 2017 · 2 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- PAUL GAROFOLOExecutive Officer, Director
- BARY BAILEYDirector
- STUART PETERSONDirector
- Offering amount
- $14M
- Amount sold
- $7M
- First sale
- Sep 2017
- Incorporated
- Corporation, Delaware, 2015
- Federal exemptions
- 06b
▶$350KraisedDec 2016 · 1 investors · BiotechnologyRule 506(b)
▶$350KraisedDec 2016 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- BARY BAILEYDirector
- GEOFFREY GLASSDirector
- NICK TAYLORExecutive Officer
- CHUCK BRAMLAGEDirector
- PAUL GAROFOLOExecutive Officer, Director
- DAVID JOHNSTONDirector
- Offering amount
- $7M
- Amount sold
- $350K
- First sale
- Dec 2016
- Incorporated
- Corporation, North Carolina, 2015
- Federal exemptions
- 06b
▶$1.3MraisedApr 2016 · 62 investors · BiotechnologyRule 506(b)
▶$1.3MraisedApr 2016 · 62 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- GEOFFREY GLASSDirector
- DAVID JOHNSTONDirector
- NICK TAYLORExecutive Officer
- PAUL GAROFOLOExecutive Officer, Director
- BARY BAILEYDirector
- CHUCK BRAMLAGEDirector
- Offering amount
- $1.5M
- Amount sold
- $1.3M
- First sale
- Jan 2016
- Incorporated
- Corporation, North Carolina, 2015
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 2
by search overlapPrecisionphage103 shared keywordsPrecisionPhage develops software and laboratory services for bacteriophage research and manufacturing, including tools for phage genome assembly, annotation, and GMP-compatible batch quality control. It serves biotechnology and pharmaceutical organizations working on phage-based approaches to antimicrobial resistance (AMR) and biosafety.
BYJU'S92 shared keywordsBYJU'S offers online learning programs, video lessons, and a personalized learning app for students in India, including tutoring and exam-preparation programs for competitive tests such as JEE and NEET.
Companies competing with Locus Biosciences for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does Locus Biosciences do?
- Locus Biosciences develops engineered bacteriophage therapies for treating bacterial infections and conditions in immunology, oncology, and CNS disorders. It uses a technology platform combining robotics, automated biobanking, AI-driven cocktail prediction, and synthetic biology, and operates a cGMP viral vector manufacturing facility for clinical trial material.
- Who founded Locus Biosciences?
- Locus Biosciences was founded by Paul Garofolo in 2015.
- Who are Locus Biosciences's investors?
- Locus Biosciences's investors include Artis Ventures, Abstract Ventures, Hemisphere Ventures LLC, Domain Associates, Longitude Capital, Starlight Ventures.
- How much funding has Locus Biosciences raised?
- Locus Biosciences has disclosed $46.3M raised across 6 of its 7 known rounds.
- Where is Locus Biosciences headquartered?
- Locus Biosciences is headquartered in Raleigh, US.